TOP TEN perturbations for 39862_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39862_at
Selected probe(set): 214226_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39862_at (214226_at) across 6674 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):2.9467192
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)

Relative Expression (log2-ratio):-2.4082031
Number of Samples:6 / 10
Experimental diphenylcyclopropenone study 1 (late)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:---
Control diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---

diphenylcyclopropenone study 1 (early) / placebo treated skin tissue

Relative Expression (log2-ratio):2.3852854
Number of Samples:10 / 11
Experimental diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---
Control placebo treated skin tissue
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days.

atopic dermatitis study 21 (lesional; whole skin) / atopic dermatitis study 21 (non-lesional; whole skin)

Relative Expression (log2-ratio):2.1882591
Number of Samples:5 / 5
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.

atopic dermatitis study 21 (lesional; epidermis) / normal epidermis tissue

Relative Expression (log2-ratio):2.071331
Number of Samples:5 / 10
Experimental atopic dermatitis study 21 (lesional; epidermis)
Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal epidermis tissue
Epidermal samples isolated from healthy subjects by laser capture microdissection.

atopic dermatitis study 21 (lesional; epidermis) / atopic dermatitis study 21 (non-lesional; epidermis)

Relative Expression (log2-ratio):2.066742
Number of Samples:5 / 5
Experimental atopic dermatitis study 21 (lesional; epidermis)
Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control atopic dermatitis study 21 (non-lesional; epidermis)
Non-lesional epidermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.

atopic dermatitis study 12 (lesional; adults) / normal skin tissue (adults)

Relative Expression (log2-ratio):2.0500393
Number of Samples:20 / 11
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control normal skin tissue (adults)
Skin biopsy samples from healthy adults (age range 38–57 years).

atopic dermatitis study 12 (lesional; children) / normal skin tissue (children)

Relative Expression (log2-ratio):1.9150991
Number of Samples:18 / 15
Experimental atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.
Control normal skin tissue (children)
Skin biopsy samples from healthy children (age range 4 months – 3 years) without personal/familial atopy.

engineered skin substitute study 1 (late) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):1.782196
Number of Samples:3 / 2
Experimental engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

psoriasis study 11 (lesional; brodalumab; 15d; 350mg) / psoriasis study 11 (lesional; placebo; 15d)

Relative Expression (log2-ratio):-1.7594156
Number of Samples:8 / 5
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 350mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (350 mg s.c.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 15d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo.

Organism: Homo sapiens
Gene: 39862_at
Selected probe(set): 217949_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39862_at (217949_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):-2.663826
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.4657478
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

pancreatic cancer study 3 (ipmn) / normal pancreas tissue

Relative Expression (log2-ratio):-2.3970737
Number of Samples:3 / 6
Experimental pancreatic cancer study 3 (ipmn)
Intraductal papillary mucinous neoplasm from patients with pancreatic cancer.
Control normal pancreas tissue
Normal human pancreatic tissue.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.389431
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.3770418
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):2.3194876
Number of Samples:12 / 6
Experimental retina pigment epithelium study 2 (fetal)
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.2920446
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.153741
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-2.106142
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (280min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-1.9960117
Number of Samples:2 / 2
Experimental Treg activation study 1 (280min)
Regulatory T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.